RALLYBIO CORPORATION Depreciation
RALLYBIO CORPORATION (RLYB) reported Depreciation of $100.00 thousand for the 12-month period ending 2025-12-31, per its S-4/A filed 2026-08-26.
Financial Statements › Cash Flow › Operating Activities
us-gaap:Depreciation · last filed 2026-08-26
- RALLYBIO CORPORATION depreciation for fiscal 2023 was $100.00K, a 50.00% decline from fiscal 2022.
- RALLYBIO CORPORATION depreciation for fiscal 2022 was $200.00K, a 100.00% increase from fiscal 2021.
- RALLYBIO CORPORATION depreciation for fiscal 2021 was $100.00K, a 61.29% increase from fiscal 2020.
- RALLYBIO CORPORATION depreciation for fiscal 2020 was $62.00K.
| Period end | Depreciation 12 month | Depreciation 12 month as first filed |
|---|---|---|
| 2025-12-31 | $100.00K S-4/A · filed 2026-08-26 | |
| 2024-12-31 | $100.00K S-4/A · filed 2026-08-26 | |
| 2023-12-31 | $100.00K 10-K · filed 2025-03-13 | |
| 2022-12-31 | $200.00K 10-K · filed 2024-03-12 | |
| 2021-12-31 | $100.00K 10-K · filed 2023-03-06 | $109.00K 10-K · filed 2022-03-15 |
| 2020-12-31 | $62.00K 10-K · filed 2022-03-15 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Acrivon Therapeutics, Inc. (ACRV) | United States | $0.091B | -1.03 |
| ONCOLYTICS BIOTECH INC (ONCY) | $0.086B | ||
| NEONC TECHNOLOGIES HOLDINGS, INC. (NTHI) | United States | $0.086B | |
| Lexaria Bioscience Corp. (LEXX) | $0.084B | -1.92 | |
| Telomir Pharmaceuticals, Inc. (TELO) | United States | $0.084B | |
| Anixa Biosciences Inc (ANIX) | United States | $0.096B | |
| CITIUS ONCOLOGY, INC. (CTOR) | United States | $0.097B | -1.49 |
| Gain Therapeutics, Inc. (GANX) | United States | $0.080B | -4.40 |
| Milestone Pharmaceuticals Inc. (MIST) | $0.098B | -2.00 | |
| Lifevantage Corp (LFVN) | United States | $0.078B | 15.40 |